Skip to content
Screener

Intellia Therapeutics NTLA Investing Cash Flow

Investing Cash Flow at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$23.5M+120%
ALN
Alnylam PharmaceuticalsALNY
-$363.46M-157%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$410.74M-1,979%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$25.27M+120%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$7.59M-196%
Prime Medicine logo
Prime MedicinePRME
$24.03M

Other financials

Income statement

See full
Revenue$7.7M-46.2%
Operating income-$112.8M-2.5%
Net income-$106.6M-5.3%
EPS (diluted)-$0.80+18.4%

Balance sheet

See full
Cash & equivalents$106.1M-32.0%
Total debt$73.4M-28.4%
Total equity$727.7M+202%
Total assets$857.2M-4.6%

Cash flow

See full
Operating cash flow-$83.1M+16.6%
CapEx$1.8M+657%
Free cash flow-$84.9M+15.0%

Valuation

See full
Market cap$1.68B+45.7%
Enterprise value$1.65B+49.8%
P/S28.2×+6.4×

Profitability

See full
Operating margin-711.7%-149pp
Net margin-672.2%-139pp
FCF margin-586%-123pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×
Current ratio6.6×+1.5×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337952
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from sale of property and equipment90-
Purchases of marketable securities(267,358)(138,809)
Sales and maturities of marketable securities193,894341,021
Net cash (used in) provided by investing activities(75,262)201,238
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock through follow-on public offering194,580-
Net proceeds from issuance of common stock through at-the-market offerings33,56913,415
Proceeds from options exercised16-

Item 1. Financial Statements

FAQ

What is Intellia Therapeutics's investing cash flow?
Intellia Therapeutics (NTLA) reported investing cash flow of -$141.57M in Q2 2026.
How has Intellia Therapeutics's investing cash flow changed year-over-year?
Intellia Therapeutics's investing cash flow decreased by 232.4% year-over-year, from $106.91M to -$141.57M.
What is the long-term trend for Intellia Therapeutics's investing cash flow?
Over 2 years (2021 to 2025), Intellia Therapeutics's investing cash flow has grown at a -35.6% compound annual growth rate (CAGR), from -$550.78M to $228.77M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Intellia Therapeutics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude